Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Treasury Shares (2022 - 2026)

Indivior Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $2.9 million for Q1 2026.

  • For Q1 2026, Treasury Shares fell 34.6% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $2.9 million, down 34.6%, while the annual FY2025 figure was $5.0 million, 379.54% up from the prior year.
  • Treasury Shares for Q1 2026 was $2.9 million at Indivior Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $5.5 million in Q2 2025 and troughed at $1.0 million in Q4 2024.
  • A 5-year average of $3.5 million and a median of $3.7 million in 2025 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: plummeted 80.56% in 2024 and later soared 379.54% in 2025.
  • Year by year, Treasury Shares stood at $1.6 million in 2022, then soared by 242.64% to $5.3 million in 2023, then plummeted by 80.56% to $1.0 million in 2024, then soared by 379.54% to $5.0 million in 2025, then tumbled by 41.3% to $2.9 million in 2026.
  • Business Quant data shows Treasury Shares for INDV at $2.9 million in Q1 2026, $5.0 million in Q4 2025, and $2.5 million in Q3 2025.